The mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-β degradation

J Neuroinflammation. 2016 Jul 11;13(1):184. doi: 10.1186/s12974-016-0646-z.

Abstract

Background: Amyloid-β (Aβ)-stimulated microglial inflammatory responses engage mitogen-activated protein kinase (MAPK) pathways in Alzheimer's disease (AD). Mixed-lineage kinases (MLKs) regulate upstream MAPK signaling that include p38 MAPK and c-Jun amino-terminal kinase (JNK). However, whether MLK-MAPK pathways affect Aβ-mediated neuroinflammation is unknown. To this end, we investigated if URMC-099, a brain-penetrant small-molecule MLK type 3 inhibitor, can modulate Aβ trafficking and processing required for generating AD-associated microglial inflammatory responses.

Methods: Aβ1-42 (Aβ42) and/or URMC-099-treated murine microglia were investigated for phosphorylated mitogen-activated protein kinase kinase (MKK)3, MKK4 (p-MKK3, p-MKK4), p38 (p-p38), and JNK (p-JNK). These pathways were studied in tandem with the expression of the pro-inflammatory cytokines interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α. Gene expression of the anti-inflammatory cytokines, IL-4 and IL-13, was evaluated by real-time quantitative polymerase chain reaction. Aβ uptake and expression of scavenger receptors were measured. Protein trafficking was assessed by measures of endolysosomal markers using confocal microscopy.

Results: Aβ42-mediated microglial activation pathways were shown by phosphorylation of MKK3, MKK4, p38, and JNK and by expression of IL-1β, IL-6, and TNF-α. URMC-099 modulated microglial inflammatory responses with induction of IL-4 and IL-13. Phagocytosis of Aβ42 was facilitated by URMC-099 with up-regulation of scavenger receptors. Co-localization of Aβ and endolysosomal markers associated with enhanced Aβ42 degradation was observed.

Conclusions: URMC-099 reduced microglial inflammatory responses and facilitated phagolysosomal trafficking with associated Aβ degradation. These data demonstrate a new immunomodulatory role for URMC-099 to inhibit MLK and to induce microglial anti-inflammatory responses. Thus, URMC-099 may be developed further as a novel disease-modifying AD therapy.

Keywords: Alzheimer’s disease; Amyloid-β; Endolysosomal pathway; Microglia; Mixed-lineage kinase 3; Phagocytosis.

MeSH terms

  • Amyloid beta-Peptides / metabolism*
  • Amyloid beta-Peptides / pharmacology
  • Animals
  • Animals, Newborn
  • Brain / cytology
  • Cells, Cultured
  • Cytokines / genetics
  • Cytokines / metabolism*
  • Enzyme-Linked Immunosorbent Assay
  • Lysosomal-Associated Membrane Protein 1 / metabolism
  • Mice
  • Microglia / drug effects*
  • Microscopy, Confocal
  • Mitogen-Activated Protein Kinase Kinases / metabolism
  • Peptide Fragments / pharmacology
  • Protein Kinase Inhibitors / pharmacology*
  • Pyridines / pharmacology*
  • Pyrroles / pharmacology*
  • Receptors, Scavenger / genetics
  • Receptors, Scavenger / metabolism
  • Signal Transduction / drug effects
  • Statistics, Nonparametric
  • rab GTP-Binding Proteins / metabolism
  • rab7 GTP-Binding Proteins

Substances

  • Amyloid beta-Peptides
  • Cytokines
  • Lysosomal-Associated Membrane Protein 1
  • Peptide Fragments
  • Protein Kinase Inhibitors
  • Pyridines
  • Pyrroles
  • Receptors, Scavenger
  • URMC-099
  • amyloid beta-protein (1-42)
  • rab7 GTP-Binding Proteins
  • Mitogen-Activated Protein Kinase Kinases
  • rab GTP-Binding Proteins